Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/164999Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Darbà, Josep | - |
| dc.contributor.author | Ascanio, Meritxell | - |
| dc.contributor.author | Carvalho, Davide | - |
| dc.contributor.author | Conde, Vasco | - |
| dc.contributor.author | Pedersen, Kasper S. | - |
| dc.date.accessioned | 2020-06-10T08:05:43Z | - |
| dc.date.available | 2020-12-20T06:10:18Z | - |
| dc.date.issued | 2019-12-20 | - |
| dc.identifier.issn | 1646-3439 | - |
| dc.identifier.uri | http://hdl.handle.net/2445/164999 | - |
| dc.description.abstract | Objectives: To assess the cost-effectiveness of insulin degludec (degludec) versus insulin glargine (glargine) U100 from a Portuguese healthcare perspective using data from SWITCH 1 & 2 trials. - - - Methods: A short-term model estimated cost-effectiveness of degludec versus glargine U100 in type 1 diabetes (T1DM) basal bolus (B/B) and type 2 diabetes (T2DM) basal oral therapy (BOT) patients. The model captured hypoglycaemia rates and insulin dosing. Clinical outcomes were obtained from SWITCH 1 & 2. Disutilities related to hypoglycaemic events and insulin, needles and blood glucose tests costs were also included. Benefits were measured in QALYs. One-way and probabilistic sensitivity analyses were conducted (...) | - |
| dc.format.extent | 10 p. | - |
| dc.format.mimetype | application/pdf | - |
| dc.language.iso | eng | - |
| dc.publisher | Cortex - Publicacoes Tecnicas e Cientificas | - |
| dc.relation.isformatof | Versió postprint del document publicat a: http://www.revportdiabetes.com/rpd-dez-2019/ | - |
| dc.relation.ispartof | Revista Portuguesa de Diabetes, 2019, vol. 14, num. 4, p. 141-150 | - |
| dc.rights | cc-by-nc-nd (c) Cortex - Publicacoes Tecnicas e Cientificas, 2019 | - |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es | - |
| dc.source | Articles publicats en revistes (Economia) | - |
| dc.subject.classification | Anàlisi cost-benefici | - |
| dc.subject.classification | Salut pública | - |
| dc.subject.classification | Diabetis | - |
| dc.subject.classification | Insulina | - |
| dc.subject.classification | Portugal | - |
| dc.subject.other | Cost effectiveness | - |
| dc.subject.other | Public health | - |
| dc.subject.other | Diabetes | - |
| dc.subject.other | Insulin | - |
| dc.subject.other | Portugal | - |
| dc.title | Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials | - |
| dc.type | info:eu-repo/semantics/article | - |
| dc.type | info:eu-repo/semantics/acceptedVersion | - |
| dc.identifier.idgrec | 695776 | - |
| dc.date.updated | 2020-06-10T08:05:43Z | - |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
| Appears in Collections: | Articles publicats en revistes (Economia) | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 695776.pdf | 540.18 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
